Novel PTSD Treatment Advances Toward Regulatory Evaluation with New Collaboration

MAPS Public Benefit Corporation (MAPS PBC) announced today that it has selected the contract research organisation (CRO), MMS Holdings (MMS), as its CRO for the development of a New Drug Application (NDA) for MDMA-assisted therapy for PTSD. MMS will support the NDA submission by providing regulatory strategy, biostatistics, statistical programming, medical writing, medical review, publishing, and submission project management support.

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account
Topic PTSD
Compound MDMA
Visit article
Category Press Release
Published in MAPS

Companies Featured

MAPS Public Benefit Corporation (MAPS PBC) is the 'benefit above profit' corporation that is fully owned by MAPS.

Inline Feedbacks
View all comments